Chidamide monotherapy for the treatment of hepatosplenic T-cell lymphoma: A case report
10.13303/j.cjbt.issn.1004-549x.2021.06.016
- VernacularTitle:西达本胺单药治疗肝脾T细胞淋巴瘤
- Author:
Li HOU
1
;
Tong LI
2
;
Hongbing MA
1
;
Yu WU
1
Author Information
1. Department of Hematology and Laboratory, Western China Hospital, Sichuan University, Chengdu 610041, China
2. Aerospace Center Hospital
- Publication Type:Journal Article
- Keywords:
hepatosplenic T-cell lymphoma (HSTCL);
chidamide treatment
- From:
Chinese Journal of Blood Transfusion
2021;34(6):628-630
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To generate an efficacious therapeutic plan for patients suffered from Hepatosplenic T-cell lymphoma (HSTCL). 【Methods】 A patient diagnosed as HSTCL in January 2016 was observed, and chidamide monotherapy instead of traditional chemotherapy was applied due to the poor performance and infection complications of the patient. 【Results】 The patient has achieved amazing improvements after chidamide monotherapy. As we followed and evaluated recently, the patient has received partial remission and can keep durable remission for 4 years. 【Conclusion】 The study suggests that chidamide is a novel therapeuticchoice in patients with HSTCL.
